Rubus coreanus miquel ameliorates scopolamine-induced memory impairments in ICR mice

Journal of Medicinal Food

Volumn 17, Issue 10, 2014, Pages 1049-1056

  Choi, Mi Ran ^a   Lee, Min Young ^a   Hong, Ji Eun ^a   Kim, Jeong Eun ^a   Lee, Jae Yong ^a   Kim, Tae Hwan ^b   Chun, Jang Woo ^b   Shin, Hyun Kyung ^c   Kim, Eun Ji ^a  

^a Hallym University   (South Korea)

^b Research and Development Center Hitejinro Co Ltd   (South Korea)

^c Jeonnam Biofood Technology Center   (South Korea)

Author keywords

acetylcholinesterase; memory impairment; Rubus coreanus Miquel; scopolamine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTATHIONE PEROXIDASE; HERBACEOUS AGENT; MITOGEN ACTIVATED PROTEIN KINASE; SCOPOLAMINE; SUPEROXIDE DISMUTASE; PLANT EXTRACT; SCOPOLAMINE BROMIDE;

ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; BRAIN CORTEX; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOUSE; MOUSE MODEL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RUBUS; RUBUS COREANUS; ANIMAL; BRAIN; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MEMORY DISORDERS; METABOLISM; PHYTOTHERAPY;

MUS; RUBUS COREANUS;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; PHYTOTHERAPY; PLANT EXTRACTS; RUBUS; SCOPOLAMINE HYDROBROMIDE;

EID: 84911916225     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.3004     Document Type: Article

References (42)

1. Blokland A: Acetylcholine: A neurotransmitter for learning and memory? Brain Res Brain Res Rev 1995;21:285-300.
2. Terry AV, Jr., Buccafusco JJ: The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821-827.
3. Power AE, Vazdarjanova A, Mcgaugh JL: Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem 2003;80:178-193.
4. Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S: Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998;12:17-34.
5. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S: Cholinesterases: Roles in the brain during health and disease. Curr Alzheimer Res 2005;2:307-318.
6. Dekosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155.
7. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS: A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003;4:97-112.
8. Yang JH, Han SJ, Ryu JH, Jang IS, Kim DH: Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice. Biol Pharm Bull 2009;32:1710-1715.
9. Hulme EC, Lu ZL, Saldanha JW, Bee MS: Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 2003;31:29-34.
10. Araujo JA, Studzinski CM, Milgram NW: Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:411-422.
11. Beatty WW, Butters N, Janowsky DS: Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 1986;45:196-211.
12. Ko SH, Choi SW, Ye SK, Yoo S, KimHS, ChungMH: Comparison of anti-oxidant activities of seventy herbs that have been used in Korean traditional medicine. Nutr Res Pract 2008;2:143-151.
13. Choi J, Lee KT, Ha J, Yun SY, Ko CD, Jung HJ, Park HJ: Antinociceptive and antiinflammatory effects of Niga-ichigoside F1 and 23-hydroxytormentic acid obtained from Rubus coreanus. Biol Pharm Bull 2003;26:1436-1441.
14. Nam JH, Jung HJ, Choi J, Lee KT, Park HJ: The antigastropathic and anti-rheumatic effect of niga-ichigoside F1 and 23-hydroxytormentic acid isolated from the unripe fruits of Rubus coreanus in a rat model. Biol Pharm Bull 2006; 29:967-970.
15. Lee JE, Park E, Auh JH, Choi HK, Lee J, Cho S, Kim JH: Effects of a Rubus coreanus Miquel supplement on plasma antioxidant capacity in healthy Korean men. Nutr Res Pract 2011;5:429-434.
16. Kim EJ, Lee YJ, Shin HK, Park JH: Induction of apoptosis by the aqueous extract of Rubus coreanum in HT-29 human colon cancer cells. Nutrition 2005;21:1141-1148.
17. Kim Y, Kim J, Lee SM, Lee HA, Park S, Kim JH: Chemopreventive effects of Rubus coreanus Miquel on prostate cancer. Biosci Biotechnol Biochem 2012;76:737-744.
18. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
19. Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
20. Hasselmo ME: The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006;16:710-715.
21. Chang Q, Gold PE: Switching memory systems during learning: Changes in patterns of brain acetylcholine release in the hippocampus and striatum in rats. J Neurosci 2003;23:3001-3005.
22. Fadda F, Cocco S, Stancampiano R: Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats. Neuroreport 2000;11:2265-2269.
23. Kar S, Slowikowski SP, Westaway D, Mount HT: Interactions between beta-amyloid and central cholinergic neurons: Implications for Alzheimer's disease. J Psychiatry Neurosci 2004;29:427-441.
24. Oh SR, Kim SJ, Kim DH, Ryu JH, Ahn EM, Jung JW: Angelica keiskei ameliorates scopolamine-induced memory impairments in mice. Biol Pharm Bull 2013;36:82-88.
25. Lee B, Shim I, Lee H, Hahm DH: Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. J Microbiol Biotechnol 2011;21:874-883.
26. Kwon SH, Lee HK, Kim JA, Hong SI, Kim HC, Jo TH, Park YI, Lee CK, Kim YB, Lee SY, Jang CG: Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur J Pharmacol 2010;649:210-217.
27. Josselyn SA, Nguyen PV: CREB, synapses and memory disorders: Past progress and future challenges. Curr Drug Targets CNS Neurol Disord 2005;4:481-497.
28. Bartsch D, Casadio A, Karl KA, Serodio P, Kandel ER: CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell 1998;95:211-223.
29. Scott Bitner R: Cyclic AMP response element-binding protein (CREB) phosphorylation: A mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem Pharmacol 2012;83:705-714.
30. Saura CA, Valero J: The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev Neurosci 2011;22:153-169.
31. Bozon B, Kelly A, Josselyn SA, Silva AJ, Davis S, Laroche S: MAPK, CREB and zif268 are all required for the consolidation of recognition memory. Philos Trans R Soc Lond B Biol Sci 2003;358:805-814.
32. Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR: Protein kinase A as a therapeutic target for memory disorders: Rationale and challenges. Trends Mol Med 2005;11:121-128.
33. Du K, Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998;273:32377-32379.
34. Won J, Silva AJ: Molecular and cellular mechanisms of memory allocation in neuronetworks. Neurobiol Learn Mem 2008;89: 285-292.
35. Barco A, Pittenger C, Kandel ER: CREB, memory enhancement and the treatment of memory disorders: Promises, pitfalls and prospects. Expert Opin Ther Targets 2003;7:101-114.
36. Tully T, Bourtchouladze R, Scott R, Tallman J: Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2003;2:267-277.
37. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML: Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp neurol 1998;150:40-44.
38. Guglielmotto M, Tamagno E, Danni O: Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: Two sides of the same coin. Scientific World Journal 2009;9:781-791.
39. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary Eel D: Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. Pharmacol Biochem Behav 2003;76:525-533.
40. Jimenez-Jimenez FJ, Alonso-Navarro H, Ayuso-Peralta L, Jabbour- Wadih T: [Oxidative stress and Alzheimer's disease]. Rev Neurol 2006;42:419-427 (article in Spanish).
41. Schroeter H, Williams RJ, Matin R, Iversen L, Rice-Evans CA: Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic Biol Med 2000;29:1222-1233.
42. Hancianu M, Cioanca O, Mihasan M, Hritcu L: Neuroprotective effects of inhaled lavender oil on scopolamine-induced dementia via anti-oxidative activities in rats. Phytomedicine 2013;20:446-452.